Profile and outcome of patients with Warfarin Toxicity admitted in a tertiary care hospital in Bhutan: a cross-sectional study investigators and institutions by Yeshey Penjore, Thinley Dorji, Sangay Dorji, Saran Tenzin Tamang

“…The reasons for warfarin toxicity included patient dosing error and drug interactions. Warfarin therapy requires appropriate patient education, adequate facilities for follow-up and avoidance of warfarin wherever possible in clinical settings.…”
Get full text

How to manage anticoagulation for cancer-associated thrombosis and atrial fibrillation in cancer by Antonella Tufano, Antonio Coppola

“…However, the possible drug-drug interactions of DOACs and the bleeding risks in thrombocytopenic patients should be considered. …”
Get full text

Contemporary Monoclonal Antibody Utilization in Glomerular Diseases by Iyad Mansour, MD, Sangeetha Murugapandian, MD, Bekir Tanriover, MD, MPH, MBA, FAST, Bijin Thajudeen, MD

“…MAbs are preferred over traditional immunosuppressive agents because of their high specificity, reduced number of drug-drug interactions, and low toxicity, which make them a prime example of personalized medicine. …”
Get full text

Comparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohor... by Dahye Shin, Dukyong Yoon, Sun Gyo Lim, Ji Man Hong, Rae Woong Park, Jin Soo Lee

“…The risk for bleeding and potential drug interactions should be considered when prescribing both medications together. …”
Get full text

Therapy of PsO in Special Subsets of Patients by Antonella Di Cesare, Federica Ricceri, Elia Rosi, Maria Thais Fastame, Francesca Prignano

“…Actually, no specific drug recommendation is available, based only on the age of the patients, while therapeutic prescription should take into account that elderly patients have more comorbidities than younger patients, with polypharmacy and an increased risk of drug interactions. Women with psoriasis are more likely to report a worse influence of the disease on their quality of life, and they are more susceptible to the development of depression. …”
Get full text

Alteration of Pharmacokinetics of Grepafloxacin in Type 2 Diabetic Rats by Meguho Watanabe, Masaki Kobayashi, Jiro Ogura, Natsuko Takahashi, Hiroaki Yamaguchi, Ken Iseki

“…Patients with type 2 diabetes are generally treated with various pharmacological compounds and are exposed to a high risk of drug-drug interactions. However, alterations of pharmacokinetics in a type 2 diabetes model have been obscure. …”
Get full text

Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance? by Marta Szumilak, Anna Wiktorowska-Owczarek, Andrzej Stanczak

“…The single hybrid agent can modulate multiple targets involved in cancer cell proliferation, possesses a simpler pharmacokinetic profile to reduce the possibility of drug interactions occurrence, and facilitates the process of drug development. …”
Get full text

Using human metabolic enzyme profiling as an innovative technology in the drug development process by Sato, Hiroaki, 1962-

Get full text

KAJIAN DRUG RELATED PROBLEMS PASIEN HEMODIALISIS RUTIN DI RUMAH SAKIT PKU MUHAMMADIYAH YOGYAKARTA PERIODE MEI SAMPAI JULI 2010 by , Heti Rais Khasanah, , Prof. Dr. Lukman Hakim, M.Sc., Apt.

“…Type of DRPs occurring untreated indication of 2,17%, sub-therapeutic doses of 21,01%, drug overdoses of 5,79%, adverse drug reactions of 2,90%, failure to receive medication at 57,97% and 10,15% for drug interactions. From the results of blood pressure measurements predialysis 67,18 had not meet the target and 75,57% of the patients blood pressure postdialysis patient had not meet the target, while based on examination of hemoglobin found 31.29% of patients with hemoglobin in accordance with the target and 68.70 % of patients had not reached the target.…”

Editorial: computational modelling of cell and tissue processes and function. by Moore, M, Noble, D

“…The envisaged longer-term end- product is the creation of simulation models for predicting drug interactions and harmful side-effects; and their use in therapeutic and environmental health risk management. …”

Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man. by Delitala, G, Trainer, P, Oliva, O, Fanciulli, G, Grossman, A

“…There is also evidence that these drugs interact in their control of pituitary-adrenal function, although the specific hypothalamic releasing hormone involved has remained unclear. …”

Catecholaminergic modulation of indices of cognitive flexibility: a pharmaco-tDCS study by Dennison, O, Gao, J, Lim, L, Stagg, C, Aquili, L

“…However, there was no significant tDCS × drugs interaction. Interestingly, and as predicted by our model, the combined administration of tyrosine with cathodal tDCS resulted in performance that was equivalent to the control condition (i.e. tDCS sham + placebo). …”

An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans by Amisten, S, Salehi, A, Rorsman, P, Jones, P, Persaud, S

“…The islet GPCRome highlights knowledge gaps in the current understanding of islet GPCR function, and identifies GPCR/ligand/drug interactions that might affect insulin secretion, which are important for understanding the metabolic side effects of drugs. …”

Insight into the molecular mechanism of P-glycoprotein mediated drug toxicity induced by bioflavonoids: an integrated computational approach by Wongrattanakamon, Pathomwat, Lee, Vannajan Sanghiran, Nimmanpipug, Piyarat, Sirithunyalug, Busaban, Chansakaow, Sunee, Jiranusornkul, Supat

“…Thus, the applied preliminary structure-based molecular modeling approach of interactions between NBD2 and flavonoids may be gainful to realize the intimate inhibition mechanism of P-gp at NBD2 level and on the basis of the obtained data, it can be concluded that these bioflavonoids have the potential to cause herb–drug interactions or be used as lead molecules for the inhibition of P-gp (as anti-multidrug resistance agents) via the NBD2 blocking mechanism in future.…”

Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs by Altice, F.L., Kamarulzaman, A., Soriano, V.V., Schechter, M., Friedland, G.H.

“…Simultaneous clinical management of multiple comorbidities in HIV-infected drug users might result in complex pharmacokinetic drug interactions that must be adequately addressed Moreover, interventions to improve adherence to treatment, including integration of health services delivery, are needed. …”
Get full text

Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo by Yu Zhang, Dimitrios Vagiannis, Youssif Budagaga, Ziba Sabet, Ivo Hanke, Tomáš Rozkoš, Jakub Hofman

“…In the present work, we evaluated encorafenib’s possible antagonistic effects on the pharmacokinetic mechanisms of multidrug resistance (MDR), as well as its perpetrator role in drug interactions. Firstly, encorafenib potently inhibited the efflux function of the ABCC1 transporter in drug accumulation assays, while moderate and null interaction levels were recorded for ABCB1 and ABCG2, respectively. …”
Get full text

Pi-pi Stacking Mediated Cooperative Mechanism for Human Cytochrome P450 3A4 by Botao Fa, Shan Cong, Jingfang Wang

“…These findings can provide an atomic insight into the cooperative binding in CYP3A4, revealing a novel pi-pi stacking mechanism for drug-drug interactions.…”
Get full text

Update of drug-resistant tuberculosis treatment guidelines: A turning point by Elisa Vanino, Bianca Granozzi, Onno W. Akkerman, Marcela Munoz-Torrico, Fabrizio Palmieri, Barbara Seaworth, Simon Tiberi, Marina Tadolini

“…Longer (18-month) treatments remain a valid option in all cases in which shorter regimens cannot be implemented due to intolerance, drug-drug interactions, extensively drug-resistant tuberculosis, extensive forms of extrapulmonary TB, or previous failure. …”
Get full text

Antihistamines for the treatment of urticaria in Mexico by Désirée Larenas-Linnemann, Mario Sánchez-Borges, Blanca Estela Del Río-Navarro, María de Lourdes Alonzo-Romero Pareyón, César Alfonso Maldonado-García, Enrique Mendoza-López, José Antonio Ortega-Martell, Juan José Luis Sienra-Monge, Miguel Alejandro Medina-Ávalos, María Isabel Rojo-Gutiérrez, Angélica María Beirana-Palencia, Jorge Bernardo Vargas-Correa, Carlos Báez-Loyola, Ruth Ivonne Mireya Ramírez-Segura, María Graciela Guzmán-Perea

“…First generation H1-antihistamines cause a variety of adverse effects via several mechanisms: sedation (accumulation in the central nervous system), dry mouth, urinary retention, weight gain (low selectivity: stimulation of serotonin/muscarinic/alpha-adrenergic receptors) and drug interactions (substrate of CYP450-3A4). Generally second generation H1-antihistamines have a better safety profile. …”
Get full text

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland by Paul Thoueille, Susana Alves Saldanha, Fabian Schaller, Aline Munting, Matthias Cavassini, Dominique Braun, Huldrych F. Günthard, Katharina Kusejko, Bernard Surial, Hansjakob Furrer, Andri Rauch, Pilar Ustero, Alexandra Calmy, Marcel Stoeckle, Manuel Battegay, Catia Marzolini, Pascal Andre, Monia Guidi, Thierry Buclin, Laurent A. Decosterd, on behalf of the Swiss HIV Cohort Study

“…The study addresses an integrated strategy of treatment monitoring outside the stringent frame of controlled clinical trials, based on relevant patient characteristics, clinical factors, potential drug-drug interactions, and measurement of circulating blood concentrations. …”
Get full text